| 000 | 01541 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517120804.0 | ||
| 264 | 0 | _c20180221 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.12433 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOzaki, Toshinori | |
| 245 | 0 | 0 |
_aDepletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. _h[electronic resource] |
| 260 |
_bOncotarget _cNov 2016 |
||
| 300 |
_a71937-71950 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aCell Cycle Checkpoints |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCore Binding Factor Alpha 1 Subunit _xphysiology |
| 650 | 0 | 4 |
_aDeoxycytidine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aGenes, p53 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMembrane Proteins _xphysiology |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aNakamura, Mizuyo | |
| 700 | 1 | _aOgata, Takehiro | |
| 700 | 1 | _aSang, Meijie | |
| 700 | 1 | _aYoda, Hiroyuki | |
| 700 | 1 | _aHiraoka, Kiriko | |
| 700 | 1 | _aSang, Meixiang | |
| 700 | 1 | _aShimozato, Osamu | |
| 773 | 0 |
_tOncotarget _gvol. 7 _gno. 44 _gp. 71937-71950 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.12433 _zAvailable from publisher's website |
| 999 |
_c26492307 _d26492307 |
||